Acute Intermittent Hypoxia for Oppenheim Disease
This study is evaluating whether a single session of breathing in low oxygen may help people with ALS.
See full descriptionAbout the trial for Oppenheim Disease
Treatment Groups
This trial involves 2 different treatments. Acute Intermittent Hypoxia is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Eligibility
This trial is for patients born any sex aged 18 and older. There are 3 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Acute Intermittent Hypoxia will improve 2 primary outcomes and 3 secondary outcomes in patients with Oppenheim Disease. Measurement will happen over the course of 3 Hours.
Patient Q & A Section
What are the signs of oppenheim disease?
This patient's symptoms and MR imaging/MRI findings are highly suggestive of the disease, but the lack of specific pathology on surgical excision of his abdominal tumors eliminates them from the differential diagnosis. However, the presence of the aforementioned symptoms without the surgical findings of focal adenoma should still raise suspicion for this entity.
What is oppenheim disease?
Opd: Oppenheim Disease, a rare and asymptomatic disorder caused by a mutated human gene. Patients have a high tendency to develop malignancies, such as colon, hepatic, pancreatic, and [ovarian cancer](https://www.withpower.com/clinical-trials/ovarian-cancer)s, but they carry no predisposition to develop such cancers. Because, to date, no specific screening tests for oppenheim disease are available and the disease is not curable; it should be considered when a patient with unexplained and unexplained hemorrhage from the skin, mucosal membranes or uterus presents.
What are common treatments for oppenheim disease?
The management of occipital lesions is a major and challenging area for neurological surgeons. The treatment of the mass and the underlying cause is very important, both radiologically and/or therapeutically. This is based on the general principles as well as the specific lesions and their position.
How many people get oppenheim disease a year in the United States?
Despite our increasing incidence of this new disorder, there appears to be a continuing decline in the number of affected individuals since the 1960s. The age at symptom onset is increasing with the exception of the first decade of life, suggesting a probable increased risk of subsequent development of Oppenheim syndrome as a result of autoimmune and inflammatory diseases that are becoming more prevalent in the aging global population. To increase our understanding of this new disease, its epidemiologic features, and the management of patients with Oppenheim syndrome, a national database of cases should be maintained, similar to a registry of other autoimmune disorders. Further study should involve the clinical presentation and medical management of all patients diagnosed with Oppenheim syndrome.
Can oppenheim disease be cured?
The prognosis for the patient's condition after treatment must be assessed following every follow-up examination. In order to make a rational decision, the patient's life expectancy should be weighed against the risk of recurrence.
What causes oppenheim disease?
As in other cases of optic atrophy, it appears that the onset of a lesion within the optic nerve results in the rapid progress towards optic retinal atrophy. The presence of a posterior macular lesion in the early stages of the disease suggests that the lesion lies deep to the peripapillary retinal nerve.
What is the latest research for oppenheim disease?
The last two years have seen major advancements in the care of patients with oppenheim disease. The introduction of new clinical trials have led to the development of more accurate and effective treatment options for patients with this rare disease.
Has acute intermittent hypoxia proven to be more effective than a placebo?
In this randomized controlled study, AIH given every 2 min for 50 min was more effective in improving exercise tolerance and heart rate recovery in patients with cardiomyopathies, especially those with hypoxemia, than a placebo.
Does acute intermittent hypoxia improve quality of life for those with oppenheim disease?
AIH improved QOL in some but not all patients with oppenheim disease. Given the risk of decompression sickness, patients should not be exposed to the underwater environment until treatment is successful.
Is acute intermittent hypoxia safe for people?
Moderate exercise for 5 hours a day for the 6 days of acute hypoxia is as safe as normobaric hypoxia and as effective as long-term use of Oxygen therapy for those living in Antarctica with respiratory disease, regardless of initial training. Exercise, even with oxygen and in harsh conditions should be the first-line treatment for hypoxia in cold, oxygen-rich environments.
What is the primary cause of oppenheim disease?
The primary cause of this syndrome is a T-cell defect, and it appears that CD4+ T-cells are depleted from peripheral blood before it is seen in the reticular fibers of the lymphoid follicles.
Is acute intermittent hypoxia typically used in combination with any other treatments?
At present, there is insufficient information on the use of AIH with other treatment modalities. In this review, there were no conclusive findings regarding the use of AIH with other treatments. More studies are needed to verify the usefulness of AIH in the management of COPD; however, if AIH has positive effects as shown in the above two case series, there is considerable potential for improving outcomes in COPD patients.